As they should enhance tumor -specific antigen presentation by dendritic cells, tumor cell lines genetically modified to express CD154 molecules have been used in an attempt to induce protective antitumor immunity. Two murine models were used: the major histocompatibility complex ( MHC ) class I negative melanoma B16F10 and the MHC class I positive mammary adenocarcinoma TS / A. CD154 or mock -transfected B16F10 or TS / A cells were injected subcutaneously into H -2 -compatible B6D2 mice. CD154 expression by tumor cells induced a complete rejection ( in the TS / A model ) or a striking reduction ( in the B16F10 model ) of modified tumors growth, but also a significant protection against the growth of mock tumor cells injected simultaneously, either mixed with the CD154 -expressing tumor cells, or in the other flank of mice. Thirty days after CD154 -expressing tumor rejection, splenic lymphocytes from surviving tumor -free mice were able to inhibit tumor proliferation in vitro and significant amounts of IFN -were detected in the sera of these mice. Growth kinetics of mock and CD154 -expressing tumors in immunocompetent versus nude mice suggest that T lymphocytes and natural killer cells responses are implicated in this antitumor immunity. The injection of CD154 -expressing tumor cell induced an antitumor protective response, both locally and distant from the injection site. The effect was most pronounced in MHC class I expressing TS / A tumor model.
I
mmunotherapy strategies are based on the existence of tumor-associated antigens (TAAs ) against which the host is able to mount a specific immune response. Recently, immune responses have been described in tumor-bearing individuals against a large variety of mutant or nonmutant TAAs. 1 Such responses suggest that it should be possible to enhance patients' immune responses to their own tumor cells by suitable strategies. T lymphocytes play a crucial role in the host immune response to cancer, and antigen recognition alone is not sufficient for T-cell activation to effector functions. Secondary signals, such as coligation of auxiliary molecules, are also necessary to generate protective T-cell responses. Therefore, given the lack of expression of costimulatory ligands on most tumor cells, a promising approach to enhance the host immune response is the transfection of tumor cells with cDNA -encoding costimulatory molecules. We have reported that tumor cells genetically modified to express CD70, CD80, or CD154 show reduced tumorigenicity in mice models. 2 Other groups have reported contradictory results concerning the use of CD80 to induce an antitumor responses. 3 Later studies suggest that CD40 and CD70 emerge as powerful, and even superior, alternatives to CD80 for improving tumor immunogenicity in vivo. 4, 5 With the treatment of human cancer in mind, the present study aimed to establish an effective in vivo immunotherapy for murine tumors that, like human tumors, lack apparent immunogenicity. As the B and dendritic cell ( DC ) molecule CD40, and its ligand CD154 on the T cell, are believed to play an important role in immune T-cell responses, tumor cells genetically modified to express CD154 were used to induce protective antitumor responses. 6 CD40 -mediated signaling appears to be critical for DCs maturation and migration to draining lymph nodes 7 and for cytotoxic T lymphocytes ( CTL ) activation. 8 DCs are the most potent and efficient of all antigenpresenting cells ( APCs ) in the immune system. These bone marrow -derived cells are motile and specialized for antigen capture in the periphery and presentation to lymphocytes in lymphoid organs. 9 They express high levels of major histocompatibility complex class I (MHC cl I) and II (MHC cl II ) encoded gene products, adherence molecules, and costimulatory molecules on their membrane. In particular, DCs express CD40 molecule, and after interaction with its ligand CD154 on T cells, they mature and migrate to lymphoid organs and induce the activation and proliferation of CTL specific for the peptides presented by MHC cl I molecules on their surface. 10 Consequently, several groups have demonstrated that DC pulsed with antigenic peptides from TAA or tumor lysates can induce specific antitumor responses in murine models 11, 12 and in humans. 13, 14 However, the efficacy of peptide-pulsed DC might be limited in vivo because the peptides may dissociate from MHC molecules due to low peptide affinity and MHC turnover. 15 Interestingly, regressions of human metastatic renal carcinoma and melanoma were obtained after vaccination with tumor cell -DC hybrids. 16 These results are encouraging but the protocol requires the production of hybrid cells for each patient.
Therefore, in an attempt to induce protective antitumor immune responses, tumor cell lines genetically modified to express CD154 molecules were injected simultaneously with mock -transfected tumors in H -2 -compatible mice. CD154 expression on tumor cells should result in the maturation of DC around these tumors, which will process and present TAA peptides to T lymphocytes. Subsequently, CTL specific for TAA antigenic epitopes should be generated around these tumors.
In this study, two murine tumor models were used: the MHC cl I negative melanoma B16F10 and the MHC cl I positive mammary adenocarcinoma TS /A. The results show that injections of CD154 -expressing tumor cells induce the appearance of an in vivo antitumor protective immune response, both locally and also away from the injection point, and which is more efficient with the MHC cl Iexpressing tumor. Splenic lymphocytes from mice, which have rejected CD154 -expressing tumor cells, are able to inhibit in vitro tumor proliferation. The results suggest that T lymphocytes and natural killer ( NK ) cells responses are implicated in the inhibition of tumor progression.
Materials and methods

Mice
Six -to 8 -week -old female B6D2 F1/ J ( H -2 bxd ) or NMRInu ( nu/ nu) mice were purchased from Elevage Janvier (Le Genest -St -Isle, France ) and were maintained in a specific pathogen -free animal facility prior to subcutaneous (s.c. ) inoculation of tumors.
Tumor cell lines
B16F10 cell line is a MHC cl I loss variant of B16, a spontaneous melanoma of C57Bl/6 ( H -2 b ) origin kindly provided by J Galea -Lauri (London, UK ). TS /A is a tumor cell line derived from a spontaneous mammary adenocarcinoma of BALB /c ( H -2 d ) strain kindly provided by P Lollini ( Bologna, Italy ). These tumor cells were maintained in vitro by serial passages in RPMI 1640 medium (BioMédia, Boussens, France ) supplemented with 10% heat -inactivated fetal calf serum ( FCS ) ( Gibco -BRL, Cergy Pontoise, France ). Both tumor cell lines were injected to H -2-compatible B6D2 mice or athymic NMRI -nu (nu /nu ) mice. To establish s.c. tumors, 1Â10 5 cells were injected in 0.1 mL of phosphate buffered saline ( PBS ) s.c. into the flank region. Tumor growth was determined by measuring the diameter in two dimensions of the tumors. 
Assay to detect splenocytes -induced inhibitions of in vitro tumor cell proliferation
Spleens were harvested from naive or tumor-injected B6D2 mice 30 days after injections. Spleens of two mice were pooled and minced. Single-cell suspensions were prepared and red blood cells were removed with erythrocytes lysis buffer (Tris HCl 0.01 M, NH 4 Cl 0.83%, pH 7.4 ). The splenocytes were stimulated in vitro by incubating 2Â10 6 splenocytes for 7 days with 2Â10 4 irradiated (100 Gy ) tumor cells in 24 -well plates. These stimulations were performed at 378C in a 5% CO 2 humidified atmosphere in RPMI-10% FCS in the presence of 50 IU /mL hIL -2r ( Proleukin 1 ; Chiron, Suresnes, France ). The stimulated splenocytes were then harvested and cocultured with alive tumor cells at a ratio of 1000 /1 (10 6 splenocytes with 10 3 tumor cells ) in 2 mL of RPMI-10% FCS and 50 IU /mL hIL-2r for 4 days. Nonadherent cells were washed with cold PBS and the adherent alive tumor cells were then trypsinized, washed once, and resuspended in 1 mL of RPMI-10% FCS. One hundred microliters of this tumor cell suspensions was put in culture in triplicate in 96 -well round -bottomed plates. After 78 hours of culture and for the last 18 hours, the cells were pulsed with 0.5 mCi / well 3 H Thymidine (Amersham Life Science, Buckinghamshire, UK ). Cells were assayed for thymidine incorporation using a -counter. The data represent means of triplicate cultures from a single experiment representative of one additional experiment.
Statistical analysis
All in vivo experiments were performed at least three times with groups of at least five mice, and some crucial experiments were performed four times with groups of eight mice. The statistical significance of the data was determined
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Results
Effect of CD154 expression on tumor growth in vivo
Two tumor cell lines, a melanoma B16F10 and a mammary adenocarcinoma TS /A, were selected to study the efficiency of CD154 in providing protective antitumor immunity. The tumor cell lines were stably transfected with pDFG Neo control vector ( mock ) or with pDFG CD40L m Neo encoding murine CD154 protein. 2 Transfected tumor cells were selected in vitro with G418 (1 mg /mL ). The CD154 expression was tested by cytofluorometry with a FITCconjugated antibody specific for murine CD154. A single clone, which best expresses CD154 molecule, was selected for each transfectant. This expression did not alter the proliferative rate of both selected tumor cell clones in vitro ( data not shown ). The effects of CD154 expression on the in vivo growth of both tumors, after s.c. injection of 10 5 cells in H -2-compatible (B6D2 F1 /J ) mice, are shown in Figure 1 . Both mock -transfected tumors rapidly grew, whereas TS /A CD154 tumor cells were rejected (Fig 1A ) . Indeed, these injections resulted in the appearance of tumors in all mice, but in those that were injected with TS /A CD154 cells, the palpable tumors spontaneously regressed within 8-10 days. By contrast, with the B16F10 tumor model, 60% of mice injected with B16 CD154 cells (Fig 2B ) developed tumors. Nevertheless, tumor sizes showed a striking inhibition of B16 CD154 tumor growth compared to mock B16 tumor growth (Fig 1B ) . Growth of both mock tumor cells was significantly different from the growth of the CD154 -transfected tumor cells, as shown by Student's t test (P < .001 in the TS / A tumor model and P < .01 in the B16F10 tumor model ). Mock -transfected tumor cells ( TS /A or B16F10 ) grew in vitro and in vivo at the same rate as the parental wildtype cells (data not shown).
Induction of local protective immunity against mock tumor growth by coinjection of CD154 -expressing tumor cell lines
The ability of CD154 -expressing tumor cells to elicit a protective immunity against mock tumor cells development in vivo was then investigated. Mice were injected simultaneously with 10 5 mock or CD154 -expressing tumor cells alone or with a mixture of 10 5 mock plus 10 5 CD154 -expressing tumor cells. No growth of TS / A CD154 tumor cells alone or mixed with TS /A mock tumor cells was observed, whereas mock TS /A tumors grew in all tested mice. Indeed, the mice injected with TS /A mock tumor cells had developed tumors 15 days after injections, whereas the mice injected with TS /A CD154 cells alone or mixed with TS /A mock cells were disease-free 60 days after tumor injection ( Fig 2A ) . On the contrary, a growth of B16 CD154 tumor cells alone or mixed with B16 mock tumor cells was observed in 60% and 67% of mice, respectively (Fig 2B ) , which was less but still significantly different ( P < .01 by Student's t test ) from the growth of B16 mock tumor cells alone in all mice.
Induction of contralateral protective immunity against mock tumor growth by injection of CD154 -expressing tumor cell lines
Mice were injected simultaneously with 10 5 mock tumor cells in the right flank and 10 5 CD154 -expressing tumor cells in the left flank. A significant protective effect was observed in the TS /A model because 43% of mice was protected against TS /A mock tumor growth (Fig 3A ) . These mice remain tumor-free for at least 60 days after tumor cell inoculation. In the B16F10 tumor model, no protective effect was observed as all mice developed mock tumors (Fig 3B ) . 
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Involvement of T lymphocytes and NK cells in CD154 -transfected tumor cells rejection
To evaluate the involvement of T lymphocytes and/or NK cells in CD154 -expressing tumor rejection, mock and CD154 transfected tumor cells were injected in parallel into athymic T cell -deficient NMRI nu /nu mice and into H -2-compatible and immunocompetent B6D2 mice.
The s.c. injections of B16 mock or B16 CD154 tumor cells in nude mice gave rise to similar growth kinetics, whereas growth kinetics was statistically different (as shown by Student's t test, P < .01) when these cells were injected in B6D2 mice ( Fig 4B ) . The data illustrate one experiment representative of two others. These results suggest that Tlymphocyte responses are mostly implicated in the slowing down of the B16 CD154 tumor growth observed in immunocompetent B6D2 mice. On the contrary, no immune T-cell responses seemed to be induced by B16 mock cells, as similar growth kinetics was observed when B16 mock tumor cells were injected either into NMRI nu /nu or into B6D2 mice (Fig 4B ) .
In the mammary adenocarcinoma model, the slowing down of TS /A mock tumor growth in B6D2 mice compared to NMRI nu /nu mice suggests that T-cell responses are implicated in this antitumor immune response (Fig 4A ) . The data illustrate one experiment representative of two others. Furthermore, s.c. injections of TS /A mock or TS / A CD154 tumor cells in nude mice gave rise to different growth kinetics (Fig 4A ) . This difference is statistically significant ( P <0.1 by Student's t test ). This suggests that not only T lymphocytes but also NK cells are implicated in the rejection of TS / A CD154 tumor cells in immunocompetent B6D2 mice. Surprisingly, the establishment of mock and CD154 -expressing tumors in nude mice suggests that NK cells 
CD154
In Vivo** Figure 5 In vivo and in vitro activated splenocytes induce inhibition of in vitro tumor cell proliferation. Splenic cells were harvested from naive mice ( black column ) or from surviving tumor -free mice 30 days after CD154 -expressing TS / A tumor rejection ( white column ) or CD154 -expressing B16F10 tumor rejection ( hatched column ). These splenocytes were stimulated in vitro for 7 days with the relevant irradiated mock -transfected or CD154 -expressing tumor cells in the presence of 50 UI / mL of hIL -2r. Then they were cocultured at a ratio of 1000 / 1 with the four tumor cell lines, TS / A CD154, TS / A mock, B16 CD154, or B16 mock, and the proliferation of these tumor cells was assessed by Generation and characterization of in vivo -and in vitro -stimulated splenocytes able to inhibit tumor cell proliferation in vitro
To investigate the ability of mock or CD154 TS / A or B16F10 tumor cell lines to prime spleen cells and to induce tumor-specific cytotoxic cells, splenocytes from B6D2 mice were cocultured for 7 days with irradiated ( 100 Gy ) tumor cells in the presence of 50 IU /mL hIL-2r. Splenocytes were collected either from naive mice or from mice 30 days after total or partial rejection of CD154 -expressing tumors. By chromium release test, no significant cytotoxicity toward tumor cells was observed with splenocytes from naive mice and a very low cytotoxicity was observed with spleen cells from mice after TS /A CD154 tumor cell rejection (15% lysis of tumor cells at a ratio of 100 effector cells /1 tumor cell ) ( data not shown). However, these in vitro restimulated splenocytes were able to inhibit in vitro the proliferation of mock or CD154 TS / A or B16F10 tumor cells (Fig 5 ) . The in vitro restimulation of splenocytes could be achieved by mock or CD154 tumor cells, but the stimulation with mock tumor cells seemed less efficient. This antitumoral activity was only detectable in spleen cells collected from surviving tumor-free mice and not from naive mice suggesting an in vivo priming. However, this activity was not antigenspecific because the in vitro proliferation of B16F10 tumor cells was inhibited by spleen cells collected either from TS / A CD154 or B16 CD154 tumor-injected mice (Fig 5 ) . This figure illustrates the results of one experiment representative of two.
Discussion
The aim of the new generation of therapies using the immune system to cure tumors is to build on the preexisting immune repertoire and to enhance the T-cell response to a level capable of tumor rejection. T-cell responses should be enhanced because tumor-specific activated T lymphocytes, either CD4 + or CD8 + , are expected to have the capacity to migrate and eliminate metastatic disease. Recent reports from our laboratory demonstrated that ''vaccination'' using tumor cell lines genetically modified to express CD70 and CD80 molecules could induce a protective immunity in a CD4 + and CD8 + T lymphocyte -dependent manner 2, 4 and that this protection does not involve NK cells response. 17 Our new approach, which consists in the injection of CD154 -expressing tumor cell lines, favors the tumor rejection by enhancing specific and nonspecific cellular immune responses, especially in a MHC cl I positive tumor model.
In both establishment and protection experiments, injections of CD154 -expressing tumor cells have shown that such cells have a stimulatory capacity that leads to partial or even complete rejection of mock tumor cells. Furthermore, the mice that have rejected TS / A CD154 tumors remain able to reject mock tumor cells for at least 1 month. Protective immunity induced by CD154 -expressing tumor cells is stronger in the MHC cl I positive tumor model ( TS /A ), which is consistent with the fact that CTL, probably induced after DC maturation, could only kill MHC cl I positive tumor cells. However H -2 class I expression in vivo is upregulated in the B16 CD154 transfectants ( data not shown), which can explain the implication of T lymphocytes in immune response against these tumor cells. Furthermore, DC maturation should also induce CD4 + T-cell responses, which could eliminate MHC cl I and cl II negative tumor cells in vivo by the indirect effects of IFN -, as recently described. 18 The lower efficacy of CD154 -expressing tumor cell injection in the B16F10 tumor model could also be explained by other features of the cells. Indeed, B16F10 is a highly virulent melanoma cell line that grows in vitro and in vivo much faster than TS /A cells and its minimal tumorigenic dose is at least 10 times lower. Furthermore, TS /A CD154 tumor cells, unlike B16 CD154 cells, seemed to be sensitive to NK response as shown by the injections in nude mice. Moreover, a significant amount of IFN -was detected in the sera of the B6D2 mice injected with TS /A CD154 tumor cells. The secretion of IFN -, induced by injections of CD154 -expressing tumor cells, should help to reject MHC cl II negative tumors because the presence of IFN -would favor the reexpression of MHC molecules on tumor cells. 19 Such murine vaccination protocols are investigated to evaluate their potential for a future use in human therapy. The nonspecific component of the protection we have induced with CD154 -expressing TS / A tumor cells could be particularly encouraging for future human models in helping to design a single or few modified tumors that could be used for nearly every patient, without need to prepare modified cells from each patient. Vaccination strategies with DCs, engineered to express MAGE -1, CD154, or granulocyte / macrophage colony -stimulating factor, were shown to induce a stronger antitumor therapeutic effect than modified tumors. 20, 21 However, these protocols require modified DCs or tumor cell -DC hybrid to be obtained for each individual patient. In our protocol, the expression of CD154 molecule on tumor cells could induce the maturation of DCs near the tumors and therefore induce antitumor therapeutic effect. Furthermore, direct presentation of TAA by the tumor cells themselves should favor the induction of specific effector CTLs. As a matter of fact, it has been recently described that cross -presentation is necessary and sufficient for the induction of memory CTLs, but optimal induction of effector CTLs requires direct antigen presentation by tumor cells. 22 While the mechanisms implicated in the protective immune response induced by our vaccination protocol need to be further defined, these data suggest the possibility of additional strategies for immunotherapy.
